Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis
Allergy2020Vol. 76(4), pp. 1268–1270
Citations Over TimeTop 10% of 2020 papers
Maria Helena Rohner, Kathrin Thormann, Simone Cazzaniga, Shída Yousefi, Hans‐Uwe Simon, Christoph Schlapbach, Dagmar Simon
Abstract
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Related Papers
- Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.(2016)
- → Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial(2018)4 cited
- → Case report of the dupilumab applying in atopic dermatitis child(2021)1 cited
- → The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report(2021)1 cited
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)